Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetuximab biobetter - Sinomab/Sorrento

Next Previous
Drug Profile

Cetuximab biobetter - Sinomab/Sorrento

Alternative Names: cetuximab beta; Cetuximab biosimilar/biobetter - Sinomab/Sorrento; CMAB 009; Enlituo; STI-001

Latest Information Update: 05 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mabtech
  • Developer Shanghai Biomabs Pharmaceuticals; Shanghai Zhangjiang Biotechnology; Sinomab
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer

Most Recent Events

  • 10 May 2025 Efficacy and adverse events data from a phase III trial in Colorectal cancer released by Simcere Zaiming
  • 13 Jan 2025 Launched for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in China (IV) before January 2025
  • 26 Jun 2024 Registered for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in China (IV)- First global approval

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top